"The data to be presented at ISTH showcase our gene therapy expertise in hemophilia B with both long-term safety and durability from our ongoing Phase 1-2 study of AMT-060 , and up to 9 months of safety and FIX activity in the Phase IIb dose-confirmation study of AMT-061," stated Matt Kapusta, chief executive officer at uniQure. "We also are very pleased to have an oral presentation on our novel gene therapy approach to treat hemophilia A and look forward to presenting these data at the conference."
Specific details on uniQure's presentations at ISTH include:
uniQure is delivering on the promise of gene therapy - single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with hemophilia, Huntington's disease and other severe genetic diseases. www.uniQure.com
|FOR INVESTORS:||FOR MEDIA:|
|Maria E. Cantor||Eva M. Mulder||Tom Malone|
|Direct: 339-970-7536||Direct: +31 20 240 6103||Direct: 339-970-7558|
|Mobile: 617-680-9452||Mobile: +31 6 52 33 15 79||Mobile:339-223-8541|
To read more Press Release articles, click here.